Immunome | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 0

LB filings
2025.11.06 22:05

Revenue: As of FY2025 Q3, the actual value is USD 0, missing the estimate of USD 727.27 K.

EPS: As of FY2025 Q3, the actual value is USD -0.65, missing the estimate of USD -0.5759.

EBIT: As of FY2025 Q3, the actual value is USD -62.82 M.

Segment Revenue

  • Collaboration Revenue: For the nine months ended September 30, 2025, collaboration revenue was $6.941 million, compared to $6.303 million for the same period in 2024, reflecting an increase of $0.638 million.

Operational Metrics

  • Net Loss: The net loss for the nine months ended September 30, 2025, was - $142.494 million, compared to - $212.714 million for the same period in 2024, showing a reduction in net loss by $70.220 million.
  • Research and Development Expenses: Increased by $44.864 million, from $81.652 million for the nine months ended September 30, 2024, to $126.516 million for the same period in 2025.
  • General and Administrative Expenses: Increased by $9.168 million, from $22.509 million for the nine months ended September 30, 2024, to $31.677 million for the same period in 2025.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $142.966 million, compared to - $68.734 million for the same period in 2024.
  • Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $64.802 million, compared to net cash used of - $94.821 million for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $207.562 million, compared to $220.444 million for the same period in 2024.

Unique Metrics

  • Share-Based Compensation Expense: Total share-based compensation expense for the nine months ended September 30, 2025, was $17.797 million, compared to $10.278 million for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: Immunome, Inc. plans to continue advancing its pipeline, which includes three clinical assets and three preclinical assets. The company expects to report topline data from the Phase 3 trial of Varegacestat in the second half of 2025 and plans to initiate a Phase 1 trial for IM-3050 in early 2026.
  • Non-Core Business: The company is investing in discovery efforts to expand its pipeline, focusing on additional ADC programs and developing a diverse pipeline of ADCs.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.